AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02822911 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alcohol Used Disorders Identification Test (AUDIT C)
Description: The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women.
Study NCT02822911 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Carbohydrate deficient transferrin
Description: Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
Study NCT02822911 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gamma glutamyl transpeptidase
Description: Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
Study NCT02822911 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mean Corpuscular Volume
Description: Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
Study NCT02836860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tactile stimuli
Description: Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
Study NCT05600413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of Placebo (crystalline cellulose)
Study NCT03789708 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
Study NCT03561064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Eligible participants will receive CBT-I by a licensed clinical psychologist.
Study NCT02070666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective mechanical ventilation
Description: Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~* Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure \< 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~* Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cmH2O
Study NCT02070666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~* Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~  · FiO2 > 0.21 to maintain oxygen saturation 90-92%.~* PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~* Plateau pressure ≤ 25 cm H2O.
Study NCT02070666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dead space
Description: Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
Study NCT02070666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dead space
Description: Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
Study NCT01698125 — intervention group
Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
Study NCT00534300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
Study NCT00534300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Intravenous infusion, 100 mL, 25mL/h
Study NCT00851669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)
Description: Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
Study NCT00851669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individual psychotherapy following usual care practice in a chemical dependency treatment program.
Study NCT01472146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zo-Nantax
Description: Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg \[loading dose\] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy
Study NCT03674047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
Study NCT01432613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI-oriented muscle biopsy
Description: Orientation of muscle biopsy according to the MRI results
Study NCT03324945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessments
Description: Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
Study NCT01665248 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 18-F Sodium Fluoride Uptake in Positron emission tomography
Study NCT00535145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU), Paliperidone ER
Description: Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
Study NCT03267966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Leeds Pathology Protocol (LEEPP)
Description: LEEPP includes: 1) multicolor inking; 2) axial slicing; 3) circumferential margin; 4) 1-mm clearance
Study NCT02878772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinpocetine
Description: 30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
Study NCT02878772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 100mg, once daily, oral medication
Study NCT02878772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100mg, once daily, oral medication
Study NCT03260140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral lifestyle intervention
Description: The investigators will provide participants with the behavioral lifestyle intervention
Study NCT03789708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder, easily soluble
Study NCT01909544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatiguing exercise
Description: All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
Study NCT01909544 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fatiguing exercise
Description: All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
Study NCT02526784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Study NCT02882035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OFA
Study NCT04056611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 250 mg
Description: JNJ-53718678 250 mg will be administered orally.
Study NCT04056611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT04056611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 125 mg
Description: JNJ-53718678 125 mg will be administered orally.
Study NCT00003375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT00003375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT00003375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00003375 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01042639 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
Study NCT01625130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprout homogenate
Description: Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
Study NCT01625130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alfalfa sprout homogenate
Description: 200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
Study NCT01042639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
Study NCT01042639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: passive physical activity
Description: extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
Study NCT04773717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: 200mg/kg/24h in four equal parts
Study NCT04773717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same regimen as ascorbic acid.
Study NCT03438227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron dextran
Description: Single intravenous infusion of iron dextran 1000mg.
Study NCT03127280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Track foley removal
Description: Foley catheter is removed at 4 hours after surgery
Study NCT03438227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate 325mg
Description: Oral iron supplementation with ferrous sulfate 325mg one to three times daily
Study NCT04712149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weekly digital follow up
Description: weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
Study NCT01570348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT
Study NCT01570348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01570348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01570348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01570348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01570348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid
Description: Given PO
Study NCT01570348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02526784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Study NCT01215851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg tablet, once daily for 14 days
Study NCT01215851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Dosed by Weight
Study NCT00229593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestorone gel
Description: 2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
Study NCT01215851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
Study NCT01215851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour e-275
Study NCT01215851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: moxifloxacin 400 mg
Study NCT04572334 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Auto and Subjective Refraction
Description: All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
Study NCT03172143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenteric Sparing Ileocolic Resection
Description: In this resection, the mesentery will be spared, or left in situ during resection.
Study NCT03172143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Ligation Ileocolic Resection
Description: In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen.
Study NCT02681393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure and Telephone Support
Description: Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
Study NCT02681393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Participants will receive both the Aerobic Exercise After Stroke educational brochure.
Study NCT01336946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho educational and behavioural group sessions
Description: 10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
Study NCT03198156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
Study NCT03198156 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study NCT00871078 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography (OCT)
Description: Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
Study NCT00871078 — intervention group
Intervention type: DEVICE
Intervention: Frequency Doubling Technology (FDT) perimeter
Description: 24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
Study NCT01455480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPh201, botanical drug product
Description: topical
Study NCT00613106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HZT-501
Description: Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
Study NCT00613106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
Study NCT01459692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Exposure
Description: Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
Study NCT04265131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
Study NCT00414375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation on Admission
Description: Laparoscopic appendectomy on admission
Study NCT00414375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage and Interval Appendectomy
Description: drainage with interval appendectomy
Study NCT05236166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rapid withdrawal of antiepileptic
Description: Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Study NCT05236166 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Slow withdrawal of antiepileptic
Description: Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide
Study NCT02359656 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical treatment
Description: C1-C1 arthrodesis
Study NCT02359656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non operative treatment for odontoid non unions
Description: specific non operative treatment protocol
Study NCT02209467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group balance training
Description: Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
Study NCT01361984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol
Description: Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
Study NCT01336946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking session
Description: A weekly supervised walking session (30 minutes) in a 10-week period.
Study NCT03132922 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Description: Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
Study NCT03132922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Description: Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells
Study NCT01361984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
Study NCT02616731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC